Complaints of Eliquis and internal bleeding have been filed throughout the country, with patients alleging they were not adequately warned against these complications. These complications can be potentially deadly, as these internal bleeding injury reports indicate patients needed emergency intervention to resolve the problem.

Eliquis is the third in a series of new generation anticoagulants which were released to compete directly with each other and the original blood thinner warfarin. The new generation anticoagulants have been advertised to be more efficient than warfarin, along with having the convenience of being prescribed in a single dose.

However, the new generation anticoagulants do not have a readily available bleeding remedy in the case of internal bleeding. This differs from warfarin, for which doctors could administer vitamin K to stop any internal bleeding. Reported incidents associated with Eliquis and internal bleeding include:

• Gastrointestinal Bleeding
• Rectal Bleeding
• Kidney Bleeding
• Cerebral Bleeding
• Death

Eliquis was released to market in 2012, which was only one year after anticoagulant Xarelto and two years after Pradaxa.

Before the release of Pradaxa, there had been no other anticoagulants released into the United States since the release of warfarin in the 1960s. The release of Pradaxa was considered an exciting breakthrough, as it paved the way for the two other anticoagulants.

Overview of Eliquis and Internal Bleeding Concerns

Initially, patients were excited for the release of Eliquis and the other new generation anticoagulants, but it did not take long for patients to report incidents of internal bleeding.

Anticoagulants work by inhibiting the body’s clotting mechanism and improving the overall circulation process. However, they also prevent the body from recovering from internal bleeding, which can possibly result in death.

Eliquis and internal bleeding reports had been submitted since the drug’s release, with patients alleging they were not warned that there was no bleeding antidote and that they were promised Eliquis would be better than its predecessors.

It is important to note that before Eliquis was released, the FDA was concerned over problems with pre-clinical trials. This concern resulted in a later release date, but the concern of Eliquis and internal bleeding remained prevalent in the medical community.

Even though this was vital safety information, Pfizer Inc. and Bristol Myers Squibb had allegedly failed to disclose this information to the public. Many patients allege they had suffered avoidable incidents with Eliquis and internal bleeding, and that they never would have taken the medication if they had known the risks.

Many patients have filed legal action against the manufacturers for allegedly failing to warn them against Eliquis bleeding complications.